Rationale, aims, and objectives Use of continuous subcutaneous insulin infusion therapy in type 1 diabetes management is high. However, the incorporation of this technology into self-care is not without challenges, and the support of an appropriately skilled health care team is recommended. This study aimed to examine the support context for patients using continuous subcutaneous insulin infusion therapy from the health care professional perspective, as well as contextual influences for health care professionals and their patients.
consistently increased by an average of 107 to 140 new users each month from 2004 to 2010, 7 with most (70%) users situated in major cities. 7, 9 In Australia, it is younger people with T1D who predominantly choose CSII technology, with approximately 1 in every 2 CSII users under the age of 25 years. 7 In the groups in which CSII is likely to be beneficial, usage is affected by many factors. For instance, uptake can be influenced by the capacity of the individual to pay for the device and the provision of expert staff. Therefore, funding policies and related processes are important, and vary across countries. A CSII device may be provided for patients with T1D, irrespective of financial circumstance in Ontario, Canada, for example, 10, 11 whilst in Australia,
the government provides limited means tested funding for lowincome families with children with T1D. 12 CSII devices in Australia may also be obtained through personal finance, clinical trial enrolment, charitable donations, or private health insurance, which often entails a lengthy application process and hospital admission at the time of CSII commencement. Most (88%) CSII users in Australia receive financial assistance to acquire their device, with almost all (97%) using private health insurance. 7 The consequence of this method of purchase is that usage is more commonplace in higher socioeconomic areas (14% versus 6%) [43] . Regardless of age, the consumables needed for patients with T1D to use CSII technology are subsidised by the Australian Government, subject to eligibility criteria, as part of the National Diabetes Services Scheme. 13 CSII use almost always necessitates support from an appropriately skilled multidisciplinary health care professional (HCP) team, 7, [14] [15] [16] [17] to determine insulin dosage algorithms, provide education and strategies to manage risks, and achieve the anticipated benefits of CSII therapy. 18, 19 However, many Australian health care services are facing difficulty in meeting the increasing service support demand for CSII use. 20 Despite these well-known service and staffing concerns, there is little information about how patients using CSII therapy are supported from the perspective of responsible
HCPs. This information is needed for comprehensive service planning and quality assessment processes, particularly for those living outside metropolitan areas and young people. This study aimed to examine from the HCP perspective the support context for patients using CSII therapy, as well as contextual influences for HCPs and their patients. patients.
| METHODS
An overarching theme of difficulties, disconnections, and disarray emerged from the data. Difficulties occurred partly as a result of the availability and range of appropriate CSII expertise, which was perceived to exert a pervasive effect. This was in addition to barriers to access to CSII devices, consequent to government and private health insurance policy conditions. A lack of shared access to documentation and communication between adult and paediatric services, between separate components of the health service, and with HCPs across organisations, resulted in disconnections that hindered a consistent, coordinated, and informed approach to care. Finally, disarray followed the absence of consensus or definition for some key organisational processes and the subsequent delivery of care that was sometimes not standardised or consistent. There was also no consensus or policy for the specific training processes required by HCPs to provide CSIIrelated care.
| Shortages of HCP expertise
Participants (particularly those working in nonmetropolitan locations)
expressed frustration with the lack of specific HCP expertise available for their patients, which they considered essential to support CSII use: This apparent failure of the system to acknowledge and engage with this care need occurred across the continuum of care, including whilst the patient was admitted to hospital, unwell, and in need of support. This was most commonly reported in nonmetropolitan areas.
The consequences of the lack of CSII expertise were far reaching:
those experts that were available had limited time, so extra efforts had to be made by nonexpert staff to maximise the experts' time to address patients' issues. This could occur in metropolitan areas as well, as explained by a diabetes nurse educator: The lack of expertise in hospital settings also meant that expert staff (predominantly the diabetes nurse educators) reported commonly going above and beyond their work requirements by providing personal telephone numbers to patients and their immediate families.
However, the processes applied in identifying who required this extra support and for whom the HCPs were willing to disrupt their home life were unclear, but it was obvious that some degree of personal risk was perceived by participants: Collectively, from HCPs' perspectives, issues illustrated difficulties, disconnections, and disarray in the support for patients using CSII, and how this context functions for HCPs and their patients. Inequities and uncoordinated health care were described. This reflected lack of specific expertise in some locations but also lack of teamwork and common agreed care policies and processes, all undermined by lack of common data systems, communication infrastructure, and connectivity. This left unsupported individuals unwilling to contribute to CSII care, and forced others to decide for themselves which patients received what forms of support.
HCPs perceived benefits and shortfalls accruing to government and private health insurance policy conditions. Government policy recognised the importance of supporting equity of access for disadvantaged children. However, eligibility for the CSII device subsidy ceased at age 18 years, whereas the economic disadvantage could persist beyond this. Private health insurers requiring a hospital admission for CSII commencement irrespective of clinical need potentially benefited some patients but unnecessarily burdened others and the public health care system, causing further difficulties and disarray.
| DISCUSSION
This study provides insights into HCPs' perspectives of the complexity of providing support for patients using CSII therapy across diverse contexts, and lays out a platform for further research and service innovation. Previous local and international research focusing on service support for T1D, and chronic disease in general, have also demonstrated deficiencies in planning and provision of specialist HCP expertise and management. [23] [24] [25] [26] This group of HCPs indicated that these were live issues not just for patients but for their health care
providers.
CSII users need ongoing support and monitoring, and their health care teams need to be able to deliver this, to provide the best chance to delay or deter the development of vascular complications that are seen in people with T1D at young ages, 27, 28 and their associated costs. 29 Economic analysis under research conditions has demonstrated the benefit of CSII versus multiple daily injections. 30 What is needed now is to put into daily clinical practice those elements that are required to translate the benefits seen in research into 'business as usual' clinical practice. The findings of this study flag important deficits that may need attention, in order for this to occur.
Ways to promote and support engagement, both for patients and HCPs, should be considered. 20 Eligibility criteria for a CSII device subsidy from the Australian Government include the stated presence of a system to ensure follow-up and ongoing support. 12 To augment the dedicated services suggested above, phone, online, and electronic support can be considered, particularly for young people 24 and staff in rural areas. Technologies such as video conferencing may also benefit and facilitate the provision of peer support amongst diabetes HCPs, and HCP support for patients where this is otherwise locally lacking. 33 Whether CSII is the best option for a patient needs to be carefully considered, including at the time of transition, also taking account of ongoing access to appropriate supportive care.
Findings also suggest that policy innovation may also be required to enable equitable CSII access. Australian Government funding for access to a CSII device, supportive of children, could potentially be extended to cover the early adult years of eligible young people with T1D. 20 Aspects such as device and consumable provision, upgrades, and the technology support required to achieve the anticipated benefits for the entire period of CSII therapy use should be further investi- In summary, findings clearly indicate the need for policy and practice innovation to better enable staff to support patients with T1D
using CSII therapy, and to support staff providing this care, especially in nonmetropolitan areas. The need for consistent and coordinated care, and the infrastructure to facilitate this, drives an opportunity to reconfigure relationships between acute centres (often the repositories of specialist expertise) and community/primary care, where such expertise is required for preventive care but often lacking. It presents an opportunity to drive integration of care, and teamworking, across as well as within disciplines and settings.
Comprehensive service planning and monitoring involving diabetes HCPs nationwide may be required; in many geographical areas, appropriate resource allocation and use of other technologies to promote engagement with and between diabetes services may be warranted to demonstrate the comparative cost effectiveness of service redesign. Diabetes technology is advancing rapidly, requiring a skilled and responsive workforce and flexible health services capable of adapting rapidly to change. The need for service innovation and redesign is pressing.
